Radioisotopes in management of metastatic prostate cancer

Prostate Cancer Management of Metastatic Castration-resistant Prostate Cancer

The management of men with metastatic castration-resistant prostate cancer (CRPC) has taken several leaps forwards in the last two years, with the demonstration of improved overall survival with three novel agents (sipuleucel-T, cabazitaxel and abiraterone acetate) and a significant delay in skeletal-related events observed with denosumab. The pipeline of systemic therapies in prostate cancer r...

The management of metastatic prostate cancer

Bone is the most common site for metastatic deposits in men with prostate cancer. Metastatic bone disease is a catastrophic complication which can cause problems such as skeletal related events, hypercalcaemia, anaemia, spinal cord compression and signifies that the malignant process is incurable. It is important that nurses managing a caseload of patients which includes individuals with, or at...

hormone therapy in metastatic prostate cancer

only orchiectomy is still commonly used today either as a single therapy or in combination regimens. hypophysectomy & adrenalectomy showed such devastating effects on the endocrine equilibrium as to be inconsistent with an acceptable quality of life or even with survival. chemical adrenalectomy was also tried with drugs (eg. aminoglutethmide, spironolactone) leading to consequences superimposab...

Complete Radiologic Response in Metastatic Castration-Resistant Prostate Cancer Treated with Cabazitaxel

Management of Advanced/Metastatic Prostate Cancer: 2000 Update

Hormonal therapy, as currently administered, produces a dramatic response followed by a disappointing progression. Can we alter the grim prognosis of advanced prostate cancer by using novel agents, by delivering hormonal therapy earlier in the course of the disease, or by using innovative means such as intermittent therapy? Most likely we will, but not imminently. Meanwhile we need to ask, what...